ClinicalTrials.gg
CompletedNCT01563029Updated May 30, 2017Results posted

A Dose-ranging Study of Fluticasone Furoate (FF)

A Phase 2 interventional study of Fluticasone Furoate and Fluticasone Propionate in Asthma, sponsored by GlaxoSmithKline. Completed at 139 sites in 15 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
597
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
9th of 40
597 · median 102
Started
2012
with 1 other
Phase 2
12 of 40
none open now
Registered
23rd of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 12 in phase 2, and was the 23rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma. Subjects meeting all of the inclusion criteria and none of the exclusion criteria at the screening visit (Visit 1) will enter a four week run-in period during which time they will continue their current medications. Visit 2 will occur two weeks into the run-in period to allow a review of compliance with daily diary and run-in medication. At Visit 3 (end of run-in/randomization visit), subjects meeting the eligibility criteria who remain uncontrolled despite baseline therapy will be stratified based on pre screening inhaled corticosteroid (ICS) use. Once stratified, subjects will be randomised to the treatment phase of the study where they will receive one of five treatments for 12 weeks. Approx 1200 subjects ages 5 to 11 will be screened to achieve 575 randomized for a total of 115 randomized/evaluable subjects per treatment arm. Subjects will attend on-treatment visits at 2, 4, 8 and 12 weeks (Visits 4, 5, 6 and 7 respectively). A follow-up contact will be performed one week after completing study medication. All subjects must attempt spirometry measurements at Visits 1 and 3. For all subjects, a timed 24-hour urine collection for urinary cortisol and creatinine excretion will be performed prior to randomization at Visit 2 and within 7 days prior to Visit 7. All subjects must perform PEF daily between visits 1 and 7. The primary endpoint will be change from baseline in pre-dose (i.e. dosing trough) PM PEF from patient hand held electronic daily diary at Endpoint (Endpoint is defined as the mean over the last 7 days of treatment). Safety assessments include adverse events, oropharyngeal examinations, clinical chemistry, urinary cortisol, and vital signs.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from at least one parent/ legal guardian to take part in the study.:
  • Diagnosis of asthma
  • pre-bronchodilator PEF between ≥50% to ≤90% of their best post-bronchodilator value
  • Receiving therapy of short acting beta-agonist (SABA) alone, LTM, or ICS (total daily dose \<FP 200mcg or equivalent)Exclusion :

Exclusion criteria

Exclusion Criteria:

  • history of life-threatening asthma
  • history of asthma exacerbation for asthma within 6 months prior to screening.
  • Culture-documented or suspected bacterial or viral infection
  • significant abnormality or medical condition
  • Present use of any tobacco products
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
597 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder

    Drug: Fluticasone Furoate

  • Active comparator
    Arm 2

    Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder

    Drug: Fluticasone Furoate

  • Active comparator
    Arm 3

    Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder

    Drug: Fluticasone Furoate

  • Active comparator
    Arm 4

    Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder

    Drug: Fluticasone Propionate

  • Placebo comparator
    Arm 5

    Placebo inhalation powder once daily in the evening Placebo powder

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Daily Pre-dose Morning (AM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 12-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three measurements was recorded. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using an analysis of covariance (ANCOVA) model with covariates of Baseline AM PEF, actual pre-screening inhaled corticosteroid (ICS) use, region, sex, age, and treatment. Particpants analyzed included those who have PEF data for at least 2 non-missing days in the Baseline week prior to randomisation and at least 2 non-missing days after randomisation.

    Time frame: Baseline; Week 1 up to Week 12

Secondary outcomes

  1. Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period in Children Who Could Perform the Maneuver

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on treatment. Change from Baseline was calculated as the Week 12 trough FEV1 value minus the Baseline value. The Baseline FEV1 value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, actual pre-screening ICS use, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements. Only those participants available at the specified time points were analyzed.

    Time frame: Baseline, Week 12

  2. Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 12-week Treatment Period

    The number of inhalations of rescue albuterol/salbutamol aerosol (medication used to relieve symptoms immediately) used during the day and night) was recorded by the participants in a daily diary. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. The Baseline rescue-free value was defined as the percentage of rescue-free 24-hr periods from the last 7 days of the Run-in Period. Change from Baseline was calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, actual pre-screening ICS use, age, and treatment.

    Time frame: Baseline; Week 1 up to Week 12

  3. Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 12-week Treatment Period (at Week 12) minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, actual pre-screening ICS use, region, sex, age, and treatment. Particpants analyzed included those who have PEF data for at least 2 non-missing days in the Baseline week prior to randomisation and at least 2 non-missing days after randomisation.

    Time frame: Baseline; Week 1 up to Week 12

  4. Change From Baseline in PM PEF Over the Last 7 Days of the Treatment Period (Week 12)

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline in PM PEF was calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, actual pre-screening ICS use, region, sex, age, and treatment. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurements.

    Time frame: Baseline; Week 12

  5. Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 12)

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline in AM PEF was calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, pre-screening ICS use, region, sex, age, and treatment. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurements.

    Time frame: Baseline; Week 12

  6. Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 12-week Treatment Period

    Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline symptom-free value is defined as the percentage of symptom free 24-hr periods in the last 7 days of the run-in period. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, actual pre-screening ICS use, age, and treatment group.

    Time frame: Baseline; Week 1 up to Week 12

  7. Number of Withdrawals Due to Lack of Efficacy Throughout the 12-week Treatment Period

    The number of participants whose primary reason for withdrawal from the study was due to lack of efficacy is presented together with p-values for the treatment comparisons.

    Time frame: Up to Week 12

07

Results

Posted Apr 27, 2015

Participant flow

1540 participants were screened, 596 participants were randomized, and 593 participants comprise the Intent to Treat Population which include all participants who received at least one dose of study treatment. Participants were stratified at randomization according to their prior inhaled corticosteroid (ICS) use.

Participant flow — Overall Study
MilestonePlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Started119118120118118
Completed6694878589
Not completed5324333329
Withdrew: Adverse event10121
Withdrew: Lack of efficacy4216232119
Withdrew: Protocol violation12313
Withdrew: Protocol defined stopping criteria10000
Withdrew: Lost to follow-up10111
Withdrew: Physician decision35242
Withdrew: Withdrawal by subject41343

Outcome measures

PrimaryChange From Baseline in Daily Pre-dose Morning (AM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three measurements was recorded. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using an analysis of covariance (ANCOVA) model with covariates of Baseline AM PEF, actual pre-screening inhaled corticosteroid (ICS) use, region, sex, age, and treatment. Particpants analyzed included those who have PEF data for at least 2 non-missing days in the Baseline week prior to randomisation and at least 2 non-missing days after randomisation.

Time frame:
Baseline; Week 1 up to Week 12
Reported as:
Least squares mean · Liters per minute (L/min)
Change From Baseline in Daily Pre-dose Morning (AM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 12-week Treatment Period
Liters per minute (L/min)PlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BIDAverage of FF 50 µg OD and FF 100 µg OD
Change From Baseline in Daily Pre-dose Morning (AM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 12-week Treatment Period3.3 ± 2.6321.9 ± 2.6622.8 ± 2.6515.8 ± 2.6417.3 ± 2.6419.3 ± 1.86
Statistical analysis
  • Placebo vs Average of FF 50 µg OD and FF 100 µg OD · ANCOVA · p = <0.001 · Mean difference (final values): 16.0 · 95% CI 9.6 to 22.4Gate-keeper analysis
  • Placebo vs FF 100 µg OD · ANCOVA · p = <0.001 · Mean difference (final values): 12.5 · 95% CI 5.1 to 19.8Inference for FF 100 μg versus (vs) placebo and FF 50 ug versus placebo was dependent upon statistical significance (SS) having first been achieved for the average of the higher two doses of FF (FF 100 ug and 50 ug ) versus placebo comparison.
  • Placebo vs FF 50 µg OD · ANCOVA · p = <0.001 · Mean difference (final values): 19.5 · 95% CI 12.1 to 26.9Inference for FF 100 µg versus (vs) placebo and FF 50 ug versus placebo was dependent upon statistical significance (SS) having first been achieved for the average of the higher two doses of FF (FF 100 ug and 50 ug ) versus placebo comparsion.
  • Placebo vs FF 25 µg OD · ANCOVA · p = <0.001 · Mean difference (final values): 18.6 · 95% CI 11.3 to 26.0Inference for FF 25 ug versus placebo was dependent upon statistical significance (SS) having first been achieved for both the FF 100 ug versus placebo comparison and the FF 50 ug versus placebocomparison.
  • Placebo vs FP 100 µg BID · ANCOVA · p = <0.001 · Median difference (final values): 14.0 · 95% CI 6.7 to 21.4
SecondaryChange From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period in Children Who Could Perform the Maneuver

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on treatment. Change from Baseline was calculated as the Week 12 trough FEV1 value minus the Baseline value. The Baseline FEV1 value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, actual pre-screening ICS use, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements. Only those participants available at the specified time points were analyzed.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period in Children Who Could Perform the Maneuver
LitersPlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period in Children Who Could Perform the Maneuver0.128 ± 0.02640.254 ± 0.02720.150 ± 0.02520.162 ± 0.02720.192 ± 0.0262
Statistical analysis
  • Placebo vs FF 25 µg OD · ANCOVA · p = <0.001 · Mean difference (final values): 0.126 · 95% CI 0.051 to 0.201
  • Placebo vs FF 50 µg OD · ANCOVA · p = 0.551 · Mean difference (final values): 0.022 · 95% CI -0.050 to 0.094
  • Placebo vs FF 100 µg OD · ANCOVA · p = 0.379 · Mean difference (final values): 0.033 · 95% CI -0.041 to 0.108
  • Placebo vs FP 100 µg BID · ANCOVA · p = 0.089 · Mean difference (final values): 0.064 · 95% CI -0.010 to 0.137
SecondaryChange From Baseline in the Percentage of Rescue-free 24-hour Periods During the 12-week Treatment Period

The number of inhalations of rescue albuterol/salbutamol aerosol (medication used to relieve symptoms immediately) used during the day and night) was recorded by the participants in a daily diary. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. The Baseline rescue-free value was defined as the percentage of rescue-free 24-hr periods from the last 7 days of the Run-in Period. Change from Baseline was calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, actual pre-screening ICS use, age, and treatment.

Time frame:
Baseline; Week 1 up to Week 12
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 12-week Treatment Period
Percentage of rescue-free 24-hr periodsPlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 12-week Treatment Period16.5 ± 3.0124.9 ± 3.0326.3 ± 3.0328.7 ± 3.0222.7 ± 3.01
Statistical analysis
  • Placebo vs FF 25 µg OD · ANCOVA · p = 0.050 · Mean difference (final values): 8.4 · 95% CI 0.0 to 16.9
  • Placebo vs FF 50 µg OD · ANCOVA · p = 0.023 · Mean difference (final values): 9.8 · 95% CI 1.3 to 18.2
  • Placebo vs FF 100 µg OD · ANCOVA · p = 0.004 · Mean difference (final values): 12.2 · 95% CI 3.8 to 20.5
  • Placebo vs FP 100 µg BID · ANCOVA · p = 0.143 · Mean difference (final values): 6.2 · 95% CI -2.1 to 14.6
SecondaryChange From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 12-week Treatment Period (at Week 12) minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, actual pre-screening ICS use, region, sex, age, and treatment. Particpants analyzed included those who have PEF data for at least 2 non-missing days in the Baseline week prior to randomisation and at least 2 non-missing days after randomisation.

Time frame:
Baseline; Week 1 up to Week 12
Reported as:
Least squares mean · liters per minute (L/min)
Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period
liters per minute (L/min)PlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period5.1 ± 2.7616.3 ± 2.8118.5 ± 2.7713.5 ± 2.7813.1 ± 2.77
Statistical analysis
  • Placebo vs FF 25 µg OD · ANCOVA · p = 0.005 · Mean difference (final values): 11.2 · 95% CI 3.4 to 19.0
  • Placebo vs FF 50 µg OD · ANCOVA · p = <0.001 · Mean difference (final values): 13.4 · 95% CI 5.7 to 21.1
  • Placebo vs FF 100 µg OD · ANCOVA · p = <0.033 · Mean difference (final values): 8.4 · 95% CI 0.7 to 16.1
  • Placebo vs FP 100 µg BID · ANCOVA · p = 0.042 · Mean difference (final values): 8.0 · 95% CI 0.3 to 15.7
SecondaryChange From Baseline in PM PEF Over the Last 7 Days of the Treatment Period (Week 12)

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline in PM PEF was calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, actual pre-screening ICS use, region, sex, age, and treatment. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurements.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · L/min
Change From Baseline in PM PEF Over the Last 7 Days of the Treatment Period (Week 12)
L/minPlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Change From Baseline in PM PEF Over the Last 7 Days of the Treatment Period (Week 12)5.0 ± 3.7516.2 ± 3.8018.2 ± 3.7711.0 ± 3.7611.3 ± 3.75
Statistical analysis
  • Placebo vs FF 25 µg OD · ANCOVA · p = 0.037 · Mean difference (final values): 11.2 · 95% CI 0.7 to 21.7
  • Placebo vs FF 50 µg OD · ANCOVA · p = 0.014 · Mean difference (final values): 13.1 · 95% CI 2.6 to 23.6
  • Placebo vs FF 100 µg OD · ANCOVA · p = 0.266 · Mean difference (final values): 5.9 · 95% CI -4.5 to 16.3
  • Placebo vs FP 100 µg BID · ANCOVA · p = 0.242 · Mean difference (final values): 6.2 · 95% CI -4.2 to 16.6
SecondaryChange From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 12)

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline in AM PEF was calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, pre-screening ICS use, region, sex, age, and treatment. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurements.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · L/min
Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 12)
L/minPlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 12)2.7 ± 3.8123.3 ± 3.8520.6 ± 3.8314.2 ± 3.8219.3 ± 3.82
Statistical analysis
  • Placebo vs FF 25 µg OD · ANCOVA · p = <0.001 · Mean difference (final values): 20.6 · 95% CI 10.0 to 31.3
  • Placebo vs FF 50 µg OD · ANCOVA · p = 0.001 · Mean difference (final values): 17.9 · 95% CI 7.2 to 28.6
  • Placebo vs FF 100 µg OD · ANCOVA · p = 0.033 · Mean difference (final values): 11.5 · 95% CI 0.9 to 22.1
  • Placebo vs FP 100 µg BID · ANCOVA · p = 0.002 · Mean difference (final values): 16.7 · 95% CI 6.0 to 27.3
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour Periods During the 12-week Treatment Period

Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline symptom-free value is defined as the percentage of symptom free 24-hr periods in the last 7 days of the run-in period. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, actual pre-screening ICS use, age, and treatment group.

Time frame:
Baseline; Week 1 up to Week 12
Reported as:
Least squares mean · Percentage of symptom-free 24-hr periods
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 12-week Treatment Period
Percentage of symptom-free 24-hr periodsPlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 12-week Treatment Period19.0 ± 2.9021.0 ± 2.9224.7 ± 2.9022.9 ± 2.9122.0 ± 2.91
Statistical analysis
  • Placebo vs FF 25 µg OD · ANCOVA · p = 0.619 · Mean difference (final values): 2.1 · 95% CI -6.1 to 10.2
  • Placebo vs FF 50 µg OD · ANCOVA · p = 0.161 · Mean difference (final values): 5.8 · 95% CI -2.3 to 13.9
  • Placebo vs FF 100 µg OD · ANCOVA · p = 0.340 · Mean difference (final values): 3.9 · 95% CI -4.1 to 12.0
  • Placebo vs FP 100 µg BID · ANCOVA · p = 0.459 · Mean difference (final values): 3.0 · 95% CI -5.0 to 11.1
SecondaryNumber of Withdrawals Due to Lack of Efficacy Throughout the 12-week Treatment Period

The number of participants whose primary reason for withdrawal from the study was due to lack of efficacy is presented together with p-values for the treatment comparisons.

Time frame:
Up to Week 12
Reported as:
Number · Participants
Number of Withdrawals Due to Lack of Efficacy Throughout the 12-week Treatment Period
ParticipantsPlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Number of Withdrawals Due to Lack of Efficacy Throughout the 12-week Treatment Period4216232119
Statistical analysis
  • Placebo vs FF 25 µg OD · Fisher Exact · p = <0.001
  • Placebo vs FF 50 µg OD · Fisher Exact · p = 0.006
  • Placebo vs FF 100 µg OD · Fisher Exact · p = 0.003
  • Placebo vs FP 100 µg BID · Fisher Exact · p = <0.001

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the follow-up visit (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/119 (0%)20/119 (16.8%)
FF 25 µg OD—0/118 (0%)27/118 (22.9%)
FF 50 µg OD—1/120 (0.8%)20/120 (16.7%)
FF 100 µg OD—1/118 (0.8%)29/118 (24.6%)
FP 100 µg BID—0/118 (0%)24/118 (20.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
Hepatitis AInfections and infestations0/1190/1180/1201/1180/118
SyncopeNervous system disorders0/1190/1181/1200/1180/118
Most frequent other events
Most frequent other events
EventPlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BID
CoughRespiratory, thoracic and mediastinal disorders6/1197/1181/12010/1185/118
NasopharyngitisInfections and infestations4/1199/1184/1203/1184/118
HeadacheNervous system disorders2/1192/1182/1207/1184/118
PharyngitisInfections and infestations4/1192/1187/1205/1181/118
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/1196/1181/1206/1185/118
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/1196/1182/1202/1184/118
Upper respiratory tract infectionInfections and infestations3/1191/1180/1204/1183/118
PyrexiaGeneral disorders0/1194/1181/1202/1181/118
Body temperature increasedInvestigations0/1193/1180/1200/1184/118
BronchitisInfections and infestations1/1192/1184/1202/1182/118

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BIDTotal
Mean8.0 ± 1.917.9 ± 2.088.4 ± 1.627.8 ± 2.047.9 ± 1.878.0 ± 1.92
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BIDTotal
Female4941464839223
Male7077747079370
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboFF 25 µg ODFF 50 µg ODFF 100 µg ODFP 100 µg BIDTotal
African American/African Heritage4478730
American Indian or Alaskan Native241716172195
Asian -Central/South Asian Heritage101002
Asian - Japanese Heritage7752728
White - Arabic/North African Heritage120104
White - White/Caucasian/European Heritage4755515143247
Mixed Race3533403940187
08

Study locations

139 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Costa Mesa, California 92626, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Cocoa, Florida 32927, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Eagle, Idaho 83616, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    Shiloh, Illinois 62269, United States
  • GSK Investigational Site
    Lenexa, Kansas 66215, United States
  • GSK Investigational Site
    Owensboro, Kentucky 42301, United States
  • GSK Investigational Site
    Stevensville, Michigan 49127, United States
  • GSK Investigational Site
    Plymouth, Minnesota 55441, United States
  • GSK Investigational Site
    Columbia, Missouri 65203, United States
  • GSK Investigational Site
    Rolla, Missouri 65401, United States
  • GSK Investigational Site
    Corning, New York 14830, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Portland, Oregon 97202, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    El Paso, Texas 79925, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    San Antonio, Texas 78258, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    South Burlington, Vermont 05403, United States
  • GSK Investigational Site
    Plovdiv, 4002, Bulgaria
  • GSK Investigational Site
    Plovdiv, 4003, Bulgaria
  • GSK Investigational Site
    Ruse, 7000, Bulgaria
  • GSK Investigational Site
    Sofia, Bulgaria
  • GSK Investigational Site
    Tbilisi, 0119, Georgia
  • GSK Investigational Site
    Tbilisi, 0159, Georgia
  • GSK Investigational Site
    Tbilisi, 0160, Georgia
  • GSK Investigational Site
    Tbilisi, 0186, Georgia
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68163, Germany
  • GSK Investigational Site
    Berchtesgaden, Bayern 83471, Germany
  • GSK Investigational Site
    Rosenheim, Bayern 83026, Germany
  • GSK Investigational Site
    Frankfurt am Main, Hessen 60596, Germany
  • GSK Investigational Site
    Neu isenburg, Hessen 63263, Germany
  • GSK Investigational Site
    Niedernhausen, Hessen 65527, Germany
  • GSK Investigational Site
    Goettingen, Niedersachsen 37073, Germany
  • GSK Investigational Site
    Wolfenbuettel, Niedersachsen 38302, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • GSK Investigational Site
    Hamm, Nordrhein-Westfalen 59063, Germany
  • GSK Investigational Site
    Kleve-Materborn, Nordrhein-Westfalen 47533, Germany
  • GSK Investigational Site
    Telgte, Nordrhein-Westfalen 48291, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Neuhaus am Rennweg, Thueringen 98724, Germany
  • GSK Investigational Site
    Berlin, 10785, Germany
  • GSK Investigational Site
    Hamburg, 22415, Germany
  • GSK Investigational Site
    Chiba, 260-0001, Japan
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Hiroshima, 720-8520, Japan
  • GSK Investigational Site
    Hokkaido, 006-0831, Japan
  • GSK Investigational Site
    Hokkaido, 064-0821, Japan
  • GSK Investigational Site
    Hyogo, 653-0021, Japan
  • GSK Investigational Site
    Kagawa, 762-0031, Japan
  • GSK Investigational Site
    Mie, 514-0125, Japan
  • GSK Investigational Site
    Osaka, 583-8588, Japan
  • GSK Investigational Site
    Tokyo, 154-0017, Japan
  • GSK Investigational Site
    Tokyo, 157-0066, Japan
  • GSK Investigational Site
    Tokyo, 158-0097, Japan
  • GSK Investigational Site
    Wakayama, 646-8558, Japan
  • GSK Investigational Site
    Daugavpils, LV5403, Latvia
  • GSK Investigational Site
    Rezekne, LV-4601, Latvia
  • GSK Investigational Site
    Riga, LV 1003, Latvia
  • GSK Investigational Site
    Riga, LV 1004, Latvia
  • GSK Investigational Site
    Riga, LV1011, Latvia
  • GSK Investigational Site
    Guadalajara, Jalisco 44100, Mexico
  • GSK Investigational Site
    Zapopan, Jalisco 45040, Mexico
  • GSK Investigational Site
    Morelia, Michoacán 58070, Mexico
  • GSK Investigational Site
    Villahermosa, Tabasco 86100, Mexico
  • GSK Investigational Site
    Ciudad de México, 06720, Mexico
  • GSK Investigational Site
    Mexico City, 07760, Mexico
  • GSK Investigational Site
    Mexico, 04530, Mexico
  • GSK Investigational Site
    Lima 18, Lima, Peru
  • GSK Investigational Site
    Lima 27, Lima Lima 27, Peru
  • GSK Investigational Site
    San Borja, Lima Lima 41, Peru
  • GSK Investigational Site
    San Miguel, Lima Lima 32, Peru
  • GSK Investigational Site
    Lima, Lima 11, Peru
  • GSK Investigational Site
    Lima, Lima 27, Peru
  • GSK Investigational Site
    Lima, Lima 29, Peru
  • GSK Investigational Site
    Manila, 1000, Philippines
  • GSK Investigational Site
    Manila, 1003, Philippines
  • GSK Investigational Site
    Quezon City, 1113, Philippines
  • GSK Investigational Site
    Bialystok, 15-183, Poland
  • GSK Investigational Site
    Bialystok, 15-430, Poland
  • GSK Investigational Site
    Bydgoszcz, 85-046, Poland

Showing the first 100 of 139 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Oliver AJ, Covar RA, Goldfrad CH, Klein RM, Pedersen SE, Sorkness CA, Tomkins SA, Villaran C, Grigg J. Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma. J Pediatr. 2016 Nov;178:246-253.e2. doi: 10.1016/j.jpeds.2016.08.010. Epub 2016 Sep 9. PubMed 27622699 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Sep 2014, 29 months.

Results were first posted in Apr 2015, 7 months after primary completion.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 29 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2012
First posted
Mar 26, 2012
StartActual
Mar 28, 2012
Primary completionActual
Sep 24, 2014
CompletionActual
Sep 24, 2014
Results first posted
Apr 27, 2015
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01563029
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 26, 2012
Start date
Mar 28, 2012
Primary completion
Sep 24, 2014
Completion
Sep 24, 2014
Results posted
Apr 27, 2015
Last update
May 30, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Fluticasone

Start the discussion